Evidence map›Paper›PMID 41810466›Full record

ReviewAsian journal of pharmaceutical sciences2026

From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics.

Vera S Egorova, Ekaterina P Kolesova, Maya V Voronina, Evgenya R Denisova, Anastasiia O Syrocheva, Tatiana Pallaeva, Mazdak G Hakemi, Andrey A Zamyatnin, Konstantin I Ivanov, Dmitry Kostyushev and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vera S EgorovaScientific Center for Translation Medicine, Sirius University of Science and Technology, Sirius 354340, Russia.
Ekaterina P KolesovaScientific Center for Translation Medicine, Sirius University of Science and Technology, Sirius 354340, Russia.
Maya V VoroninaScientific Center for Translation Medicine, Sirius University of Science and Technology, Sirius 354340, Russia.
Evgenya R DenisovaScientific Center for Translation Medicine, Sirius University of Science and Technology, Sirius 354340, Russia.
Anastasiia O SyrochevaScientific Center for Translation Medicine, Sirius University of Science and Technology, Sirius 354340, Russia.
Tatiana PallaevaKurchatov Complex Crystallography and Photonics, NRC "Kurchatov Institute", Moscow 119333, Russia.
Mazdak G HakemiRegenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Türkiye.
Andrey A ZamyatninFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow 119234, Russia.
Konstantin I IvanovFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow 119234, Russia.
Dmitry KostyushevFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow 119234, Russia.
Sergey BrezginLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
Anastasiia KostyushevaLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
Alessandro ParodiScientific Center for Translation Medicine, Sirius University of Science and Technology, Sirius 354340, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the growing body of literature on nanovaccines, focused analyses of platforms tested in and undergoing clinical investigation remain limited. This review addresses this gap by critically examining recent advancements and highlighting nanovaccine technologies that have undergone human clinical trials. Using an extensive search on clinicaltrials.org, we explored the diverse applications of nanovaccines, including leading SARS-CoV-2 candidates and platforms targeting other infectious diseases and cancers. We also highlighted foundational research that has enabled clinical investigation of nanovaccines over the past decade, highlighting their potential to address a range of medical conditions. While many technologies have been developed to combat SARS-CoV-2, several key innovations targeted a broader spectrum of diseases. This review details these technologies, focusing on their materials and mechanisms of action in inducing immune protection, while also exploring how nanomedicine facilitates nanovaccine development and introduces novel adjuvant concepts. Finally, we provided a retrospective analysis of the development journey of these platforms, offering insights into the intellectual and technological efforts behind their clinical translation. By bridging the gap between research and application, this review aims to give readers a comprehensive understanding of how nanovaccines progress from the laboratory to clinical practice.

Indexed as

Ferritin nanovaccinesLipid nanoparticleNanovaccineOuter membrane vesiclesVirus-like nanoparticles

Identifiers

PMID41810466
PMCPMC12890808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.